Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost within the eye and when it’s depleted, the iDose is removed and replaced. Get the full story at our sister site, Drug Delivery Business News. The post Glaukos touts Ph2 glaucoma trial for drug-eluting implant appeared first on MassDevice.
Researchers at the University of Connecticut have developed a biodegradable pressure sensor that can be implanted in the body and help clinicians to monitor a variety of conditions over extended periods of time. What makes this sensor different from ...
Conditions: Glaucoma; Adherence, Patient Intervention: Drug: monitoring of adherence with medication Sponsor: Johns Hopkins University Not yet recruiting
The article by Schlenker et al1 retrospectively compares the outcomes of an ab interno gelatin stent to stand alone trabeculectomy in reducing intraocular pressure (IOP) in patients with uncontrolled open angle glaucoma. The article concludes that both procedures demonstrate equal efficacy and risk of failure. “Both proced ures had a 75% survival at approximately 10 months for complete success at an IOP ≤21 mmHg.” In terms of trabeculectomy success rates in this study these data seem to be suboptimal in comparison with recent trabeculectomy outcome data from the UK,2 where Kirwan et al demonstrate...
Authors: Rahmatnejad K, Myers JS, Falls ME, Myers SR, Waisbourd M, Hark LA Abstract PURPOSE: To determine what metrics might impact satisfaction survey responses. METHODS: A 37-question survey was administered to 249 participants. Responses were correlated to demographics, clinical factors, weather conditions, and examination timing. RESULTS: Sample consists of 55.4% female and 73.9% white, and mean age was 65.1 years. Participants were assigned to: completely satisfied (77.9%) or not completely satisfied (22.1%) groups based on their rating of glaucoma specialist on a scale of 1-10, while 10 considere...
Genome-wide association studies have identified multiple genetic variants associated with vertical cup-to-disc ratio (VCDR). Genetic risk scores (GRS) examine the aggregate genetic effect of individual variants on a trait by combining these separate genetic variants into a single measure. The purpose of this study was to construct GRS for VCDR and to determine whether the GRS are associated with VCDR and whether the GRS increase the discriminatory ability for primary open-angle glaucoma (POAG) in a Latino population.
To describe the study protocol and baseline characteristics of the African Descent and Glaucoma Evaluation Study (ADAGES) III.
ConclusionsWe concluded that glaucoma was earlier detected in children with primary congenital glaucoma, who exhibited increased corneal diameter and high percentage of Haab striae comparing to the other groups. However, these children responded successfully to any therapeutic intervention, exhibiting better BCVA and IOP values than the rest groups at the second visit.
Conclusions: Surgical excision of refractory giant papillae followed by MMG does have its advantages in reducing their corneal complications, and it should be considered early in the management of exuberant refractory giant papillae.
Conclusions: The toxicity of 0.1% brimonidine containing sodium chlorite for HCES was lower than that of ophthalmic preparations containing BAC. Reduction of the barrier function occurred after HCES were exposed to brimonidine because of widening of intercellular junctions.